Skip to main content

Start your 7-day free trial today. Get Started →

Patent Examiner Nizal S. Chandrakumar

Art Unit 1625 · Organic & Medicinal Chemistry: Heterocyclic Drug Compounds · Tech Center 1600 · 420 applications since 2021

✓ Average: easier than 55% of examiners● Free examiner data

Nizal S. Chandrakumar is a USPTO patent examiner in Art Unit 1625 (Organic & Medicinal Chemistry: Heterocyclic Drug Compounds) who has examined 420 applications in filing years 2021–2025. Examiner Chandrakumar's allowance rate is 75.9%, below the 82.1% USPTO average; the examiner ranks easier than 55% of examiners. Applicants who held an examiner interview saw a 20.0 percentage-point lift in allowance in 2024.

Draft a response to Examiner ChandrakumarSee the strategy data ↓

Data through March 2026 · Source: USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty: Average
easier than 55% of examiners
Easier45th percentileHarder
Allowance rate vs peers
Examiner Chandrakumar75.9%
Art Unit 162574.4%
USPTO average82.1%
Allowance rate
75.9%
▼ USPTO avg 82.1%
Applications
420
filing years 2021–2025
First-action allowance
36.7%
allowed on OA #1
Abandoned
15.5%
share of applications
Avg office actions
1.0
USPTO avg 1.2
Days to first OA
675
▲ USPTO 589
RCE rate
17.1%
USPTO 14.1%
Interview rate
55.5%
USPTO 21.5%

Examiner details

  • Art unit1625 · Organic & Medicinal Chemistry: Heterocyclic Drug Compounds
  • Title / gradePrimary Patent Examiner · GS-14
  • Service20 years
  • Phone(571) 272-6202
  • Email[email protected]
  • LocationAlexandria, VA 22314
  • On office actionsChandrakumar, Nizal S
Full signatory authority

Examiner Chandrakumar can allow an application without a supervisory sign-off, which is why an examiner interview can be decisive.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions546 · Organic Compounds: Heterocyclic Nitrogen (Class 532-570 Series)549 · Organic Compounds: Heterocyclic Oxygen (Class 532-570 Series)

How to improve your odds with Examiner Chandrakumar

  • The data favors an interview. Interviewed cases allowed 58.6 points higher in 2022, the largest measured lift on this docket.
  • Plan for the timeline. First office action averages 675 days vs the 589-day USPTO norm.
  • Expect a §112. Disclosure is the most-issued rejection (150), and applicants overcame it 75.3% of the time.
  • RCE outcomes are mixed year to year. 12.8 points up in 2022 but -2.2 in 2021; weigh the year-by-year table before spending the fee.
  • This docket has supported broader claims. With a 75.9% allowance rate, preserving breadth where the specification supports it has been viable.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§101 Eligibility2 issued · 100.0% overcome
§102 Novelty18 issued · 100.0% overcome
§103 Obviousness141 issued · 71.4% overcome
§112 Disclosure150 issued · 75.3% overcome
Arguments that overcame §112 rejections🔒 Members

REMARKS: Applicant respectfully traverses the rejection under 35 U.S.C. §112. The specification provides written-description and enablement support for the claimed subject matter, and the claim terms are definite when read in light of the specification by one of ordinary skill in the art, at least because ...

Read every winning §112 argumentFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Chandrakumar?

Draft a response grounded in Examiner Chandrakumar's complete prosecution history: the rejection patterns, the interview record, and the arguments that have actually worked. Powered by Boundly AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Chandrakumar.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202310.3%77.8%78.3%-0.5pp
202221.6%85.0%72.2%+12.8pp
202121.4%72.2%74.4%-2.2pp

Recent outcomes

Free🔒 Case detail: members
App #TitleOutcomeOAsArguments & redline
17/614752A Diphenylamine-Linked Chiral Bis(oxazoline) Ligand Without C2-Symmetry, Synthesis Method and Application ThereofPatented3🔒 View
18/464352Solutions for Enhancing the Effectiveness of Insecticides and Fungicides on Living Plants and Related MethodsPatented1🔒 View
18/013375Intermediate for Synthesizing Camptothecin Derivative, Preparation Method Therefor, and Use ThereofPatented0🔒 View
18/529306FormulationsPatented2🔒 View
See all 420 dispositions with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Technology & expertise

Heterocyclic compoundsMedicinal chemistryDrug compoundsOrganic synthesisTop CPC: C07D · A61K · C07C
About this examiner. Nizal S. Chandrakumar has examined 420 applications in Art Unit 1625 (Organic & Medicinal Chemistry: Heterocyclic Drug Compounds, Tech Center 1600). The docket skews toward heterocyclic compounds, medicinal chemistry, drug compounds.

Frequently asked questions

What is Examiner Nizal S. Chandrakumar's allowance rate?
Examiner Chandrakumar's allowance rate is 75.9%, compared with the 82.1% USPTO average and 74.4% for Art Unit 1625, which places Examiner Chandrakumar easier than 55% of examiners.
Is Examiner Chandrakumar a hard examiner?
Examiner Chandrakumar is about average — Examiner Chandrakumar ranks easier than 55% of examiners, in the 45th difficulty percentile (average), with a 75.9% allowance rate versus the 82.1% USPTO average and a higher RCE rate (17.1% versus 14.1%).
Do examiner interviews help with Examiner Chandrakumar?
The data says yes. Interviewed applications allowed 58.6 percentage points higher than non-interviewed ones in 2022 (87.2% versus 28.6%).
What is Examiner Chandrakumar's most common rejection?
§112 disclosure, issued 150 times in the data. Applicants overcame it 75.3% of the time, usually by amendment plus argument.
Is an RCE worth filing with Examiner Chandrakumar?
It has varied by year, so the table is the better guide. In 2023, applications with an RCE allowed at 77.8% versus 78.3% without one, but earlier years did not all run that way.
How long until the first office action from Examiner Chandrakumar?
About 675 days on average, versus the 589-day USPTO norm.
How do I contact Examiner Nizal S. Chandrakumar?
Examiner Chandrakumar can be reached by phone at (571) 272-6202 or by email at [email protected]. The examiner's direct line also appears on the first page of every office action.

Put Examiner Chandrakumar's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2025, updated monthly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Historical data is provided for informational purposes only; past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Nizal S. Chandrakumar, or see an error? Request a correction.